Aviandr is a new original drug for treating anxiety
https://doi.org/10.14412/2074-2711-2024-4-98-102
Abstract
Educational programs, psychotherapy (cognitive behavioural psychotherapy – CBP, relaxation methods), selective serotonin reuptake inhibitors (SSRIs) and selective serotonin and norepinephrine reuptake inhibitors (SNRIs) are effective in anxiety disorders (AD). In a significant proportion of patients with AD, treatment with SSRIs and SNRIs is ineffective and is discontinued due to adverse events, so the search for new drugs is needed. One of the new drugs that have been shown to be effective in AD is Aviandr, which blocks serotonergic 5-HT7, 5-HT2A, 5-HT2C and 5-HT6 receptors, adrenergic 2A, 2B and 2C receptors and histamine H1 receptors. In experimental animal models, Aviander has been shown to have significant anxiolytic and antidepressant effects. The efficacy and safety of Aviandr was investigated in patients with generalized AD (GAD) in a double-blind, placebo-controlled, randomized study conducted in 17 centers in the Russian Federation. Patients with GAD (n = 129; mean age 42.5 ± 13.1 years; 75 % women) were randomized to receive Aviandr 40 mg/day (group 1; n=42) or 60 mg/day (group 2; n = 44) or placebo (PL; group 3; n = 43) for a period of 8 weeks. Efficacy was assessed using the Hamilton Anxiety Scale (HAM-A), Hamilton Depression Scale (HAM-D) and Clinical Global Impression Scale (CGI-S). After 8 weeks of treatment, anxiety according to HAM-A scale decreased by 53.7, 47.7 and 16.3 % in group1, 2 and 3, respectively, indicating a significant (p < 0.002) benefit of Aviandr over PL and fulfilling the primary efficacy criterion. A significant (p<0.001–0.009) advantage of the treatment groups over the PL group was also observed for all secondary efficacy criteria (HAM-A, HAM-D, CGI-S, CGI-I). Adverse events occurred more frequently in group 2 (60 mg/day), but not more frequently in group 1 (40 mg/day) than in the PL group. Therefore, treatment of GAD with Aviandr at a dose of 40 mg/day is considered optimal and recommended for the treatment of AD. Currently, Aviandr starts being used in AD in our country, so the results of its use in real-life clinical practice will be available. In AD, the optimal use of Aviandr is at a dose of 40 mg/day for at least 12 weeks in combination with an educational program, if possible with CBP and effective treatment of comorbidities.
Keywords
anxiety disorder,
generalized anxiety disorder,
Aviandr,
selective serotonin reuptake inhibitors,
selective serotonin and norepinephrine reuptake inhibitors
Supporting agencies: Publication of this article has been supported by Sotex PharmFirma
About the Author
V. A. Parfenov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Vladimir Anatolyevich Parfenov
N.V. Sklifosovsky Institute of Clinical Medicine; Department of Nervous Diseases and Neurosurgery
119021; 11, Rossolimo St., Build. 1; Moscow
Competing Interests:
The article expresses the position of the author, which may
differ from that of Sotex PharmFirma
References
1. Vos T, Abajobir AA, Abbafati C, et al; GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1211-59. doi: 10.1016/S0140-6736(17)32154-2. Erratum in: Lancet. 2017 Oct 28;390(10106):e38. doi: 10.1016/S0140-6736(17)32647-8
2. Lamers F, van Oppen P, Comijs HC, et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry. 2011 Mar;72(3):341-8. doi: 10.4088/JCP.10m06176blu. Epub 2011 Jan 25.
3. Momen NC, Plana-Ripoll O, Agerbo E, et al. Association between Mental Disorders and Subsequent Medical Conditions. N Engl J Med. 2020 Apr 30;382(18):1721-31. doi: 10.1056/NEJMoa1915784
4. Meier SM, Mattheisen M, Mors O, et al. Increased mortality among people with anxiety disorders: total population study. Br J Psychiatry. 2016 Sep;209(3):216-21. doi: 10.1192/bjp.bp.115.171975. Epub 2016 Jul 7.
5. Alonso J, Liu Z, Evans-Lacko S, et al; WHO World Mental Health Survey Collaborators. Treatment gap for anxiety disorders is global: Results of the World Mental Health Surveys in 21 countries. Depress Anxiety. 2018 Mar;35(3):195-208. doi: 10.1002/da.22711. Epub 2018 Jan 22.
6. Bandelow B, Reitt M, Röver C, et al. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015 Jul;30(4):183-92. doi: 10.1097/YIC.0000000000000078
7. Windle E, Tee H, Sabitova A, et al. Association of Patient Treatment Preference With Dropout and Clinical Outcomes in Adult Psychosocial Mental Health Interventions : A Systematic Review and Meta-analysis. JAMA Psychiatry. 2020 Mar 1;77(3):294-302. doi: 10.1001/jamapsychiatry.2019.3750
8. Olthuis JV, Watt MC, Bailey K, et al. Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults. Cochrane Database Syst Rev. 2016 Mar 12;3(3):CD011565. doi: 10.1002/14651858.CD011565.pub2
9. Hoge EA, Bui E, Mete M, et al. Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial. JAMA Psychiatry. 2023 Jan 1;80(1):13-21. doi: 10.1001/jamapsychiatry.2022.3679
10. Papola D, Miguel C, Mazzaglia M, et al. Psychotherapies for Generalized Anxiety Disorder in Adults : A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. JAMA Psychiatry. 2024 Mar 1;81(3):250-9. doi: 10.1001/jamapsychiatry.2023.3971. Erratum in: JAMA Psychiatry. 2024 Mar 1;81(3):320. doi: 10.1001/jamapsychiatry.2023.5480
11. Bouchard S, Dugas MJ, Belleville G, et al. A Multisite Non-Inferiority Randomized Controlled Trial of the Efficacy of Cognitive-Behavior Therapy for Generalized Anxiety Disorder Delivered by Videoconference. J Clin Med. 2022 Oct 7;11(19):5924. doi: 10.3390/jcm11195924
12. Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder : a systematic review and network meta-analysis. Lancet. 2019 Feb 23;393(10173):768-77. doi: 10.1016/S0140-6736(18)31793-8. Epub 2019 Jan 31. Erratum in: Lancet. 2019 Apr 27;393(10182):1698. doi: 10.1016/S0140-6736(19)30857-8
13. De Vries YA, Roest AM, Burgerhof JGM, de Jonge P. Initial severity and antidepressant efficacy for anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: An individual patient data meta-analysis. Depress Anxiety. 2018 Jun;35(6):515-22. doi: 10.1002/da.22737. Epub 2018 Apr 16.
14. Breilmann J, Girlanda F, Guaiana G, et al. Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database Syst Rev. 2019 Mar 28;3(3):CD010677. doi: 10.1002/14651858.CD010677.pub2
15. Ivachtchenko AV, Lavrovsky Y, Okun I. AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620. doi: 10.3233/JAD-151146
16. Ivashchenko AA, Morozova MA, Vostokova NV, et al. Safety and efficacy of aviandr in patients with generalized anxiety disorder: A multicenter, randomized, double-blind, placebo-controlled, dose-finding, pilot study. J Psychiatr Res. 2021 Nov;143:436-44. doi: 10.1016/j.jpsychires.2021.10.008. Epub 2021 Oct 11.
17. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001 May;62(5):350-7. doi: 10.4088/jcp.v62n0508. Erratum in: J Clin Psychiatry. 2001 Aug;62(8):658.
18. Baldwin DS, den Boer JA, Lyndon G, et al. Efficacy and safety of pregabalin in generalised anxiety disorder A critical review of the literature. J Psychopharmacol. 2015 Oct;29(10):1047-60. doi: 10.1177/0269881115598411. Epub 2015 Aug 10.
Review
For citations:
Parfenov VA. Aviandr is a new original drug for treating anxiety. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(4):98-102. (In Russ.) https://doi.org/10.14412/2074-2711-2024-4-98-102
Views:
868
Email this article 